Scondotto G, De Fabritiis A, Guastarobba A, Amato A C, Filippini M
Minerva Med. 1984 Jul 14;75(28-29):1733-8.
33 subjects (28 women and 5 men), aged 22-72 and suffering from various types and degrees of venous pathology (varicose syndromes, post-phlebitic syndromes, recent thrombophlebitis) were subjected to clinical study. All patients were treated with Mesoglycan, a fibrinolysis stimulating drug, in oral doses of 2 12 mg capsules 3 times a day for 30 days. The study was intended to show the effectiveness of such treatment, and consisted of a clinical and instrumental assessment of the subjective and objective symptoms associated with venous conditions. The results obtained were analysed statistically and confirmed the therapeutic effectiveness of Mesoglycan for this type of pathology, particularly for thrombophlebitis where treatment produced early and lasting results. In conclusion, both the experimental findings and the clinical results obtained, confirm the view that Mesoglycan is a drug of choice for the prevention and treatment of venous pathologies.
33名受试者（28名女性和5名男性），年龄在22至72岁之间，患有各种类型和程度的静脉疾病（静脉曲张综合征、静脉炎后综合征、近期血栓性静脉炎），接受了临床研究。所有患者均接受了刺激纤溶的药物迈之灵治疗，口服剂量为每日3次，每次2 - 12毫克胶囊，持续30天。该研究旨在证明这种治疗方法的有效性，包括对与静脉疾病相关的主观和客观症状进行临床和仪器评估。对获得的结果进行了统计分析，证实了迈之灵对这类疾病的治疗效果，特别是对血栓性静脉炎，治疗产生了早期和持久的效果。总之，实验结果和临床结果均证实了迈之灵是预防和治疗静脉疾病的首选药物这一观点。
